Optimal Use of Combined Modality Therapy in the Treatment of Esophageal Cancer

Publication date: Available online 11 May 2017
Source:Surgical Oncology Clinics of North America
Author(s): Talha Shaikh, Joshua E. Meyer, Eric M. Horwitz

Teaser

Esophageal cancer is associated with a poor prognosis with 5-year survival rates of approximately 15% to 20%. Although patients with early stage disease may adequately be treated with a single modality, combined therapy typically consisting of neoadjuvant chemoradiation followed by esophagectomy is being adopted increasingly in patients with locally advanced disease. In patients who are not surgical candidates, definitive chemoradiation is the preferred treatment approach. All patients with newly diagnosed esophageal cancer should be evaluated in the multidisciplinary setting by a surgeon, radiation oncologist, and medical oncologist owing to the importance of each specialty in the management of these patients.


http://ift.tt/2q8G5Dv